Sci - Molecules India Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 11-12-2024
- Paid Up Capital ₹ 0.10 M
as on 11-12-2024
- Company Age 23 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 3.81 Cr
as on 11-12-2024
About Sci - Molecules India
The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹3.81 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Shilpa Wagh and Raghavendra Gaikaiwari serve as directors at the Company.
- CIN/LLPIN
U73100PN2001PTC015987
- Company No.
015987
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Mar 2001
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- LocationDatta Mandir Pune, Maharashtra
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sci - Molecules India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shilpa Wagh  | Whole-Time Director | 22-Mar-2001 | Current |
| Raghavendra Gaikaiwari | Director | 21-Feb-2019 | Current |
Financial Performance of Sci - Molecules India.
Sci - Molecules India Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Sci - Molecules India?
In 2017, Sci - Molecules India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hi Tech Biosciences India Private LimitedActive 17 years 8 monthsShilpa Wagh and Raghavendra Gaikaiwari are mutual person
Hi Tech Biosynth Private LimitedActive 8 years 10 monthsShilpa Wagh and Raghavendra Gaikaiwari are mutual person
- Hi-Tech Bio LaboratoriesActive 23 years 5 months
Shilpa Wagh and Raghavendra Gaikaiwari are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Icici Bank Limited Creation Date: 04 Feb 2011 | ₹2.55 Cr | Satisfied |
State Bank Of India Creation Date: 24 Mar 2008 | ₹1.26 Cr | Satisfied |
How Many Employees Work at Sci - Molecules India?
Unlock and access historical data on people associated with Sci - Molecules India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sci - Molecules India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sci - Molecules India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
